

Oligonucleotides: Global Markets

Market Research Report | 2026-01-21 | 125 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

Report description:

Description

Report Scope

The report provides an overview of the oligonucleotides market and analyzes market trends. It includes global revenue (\$ Million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented by product type, application and region.

By product type, the market is segmented into oligonucleotide drugs, synthesized oligos, equipment and reagents, and services. The application segment is characterized by research and therapeutics and diagnostics. The report also includes an overview of the regulatory landscape for oligonucleotides.

The report also focuses on the regional segmentation of the market. The regions covered in this study include North America, Europe, the Asia-Pacific and the rest of the world (RoW), with a focus on major countries in these regions.

The report focuses on the major driving trends and challenges affecting the market and vendor landscape. It analyzes environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report concludes with an analysis of the competitive landscape and industry structure. It also includes a dedicated section of company profiles, detailing leading market companies.

Report Includes

- 64 data tables and 55 additional tables
- In-depth analysis of the global oligonucleotides market
- Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects for the global oligonucleotide synthesis market, accompanied by a market share analysis by product, application and region
- Facts and figures pertaining to the global market dynamics, opportunities and deterrents, technological advancements, regulations, prospects and the impact of macroeconomic factors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Insights derived from Porter's Five Forces model, as well as global supply chain analyses
- Patent review, featuring key granted and published patents
- Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Company profiles of major players within the industry, including Alnylam Pharmaceuticals Inc., Biogen/Ionis Pharmaceuticals Inc., Novartis AG, and Sarepta Therapeutics Inc.

Executive Summary

Summary:

The global market for oligonucleotides was valued at \$9.1 billion in 2025 and is estimated to reach \$15.7 billion by 2030, at a compound annual growth rate (CAGR) of 11.5% from 2025 through 2030.

The use of oligonucleotides as therapeutic and diagnostic agents is an emerging field of study. Antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA (miRNA), aptamers and DNAzymes are used in the treatment of various diseases. Oligonucleotide therapeutics represent a potential new modality for treating diseases. Many potential disease targets for oligonucleotide-based therapies currently lack effective or appealing treatment options. Alnylam Pharmaceuticals Inc. is a leading company in the market, with many approved products in strategic therapeutic areas, including genetic medicine, cardio-metabolic disease, infectious disease and central nervous system (CNS) and ocular diseases. Other key companies in the market include Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc. and Jazz Pharmaceuticals. In addition to therapeutics, oligonucleotide technology is also applied in diagnostics and research.

Table of Contents:

- Table of Contents
- Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Dynamics and Growth Factors
- Emerging Technologies
- Segmental Analysis
- Regional Analysis
- Conclusion
- Chapter 2 Market Overview
- Overview
- Types of Oligonucleotides
- Mechanisms of Action of Oligonucleotides
- Oligonucleotide Synthesis Processes
- Solid Phase Chemical Synthesis
- Porter's Five Forces Analysis in the Global Oligonucleotides Market
- Macroeconomic Factor Analysis
- Impact of the U.S. Tariffs
- Growing Rare Disease Funding
- Geopolitical Factors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Chapter 3 Market Dynamics

Market Dynamics

Market Drivers

Growing Focus on Personalized Medicine

Increasing Use of Synthesized Oligos in Therapeutic Applications

Rising Prevalence of Rare Diseases

Market Restraints/Challenges

Product Withdrawals and Clinical Trial Failures

Complexities Associated with Oligos Manufacturing

High Treatment Costs of Oligonucleotide Therapeutics

Market Opportunities

Expanding Application Areas of Oligonucleotides

Expansion of Companies

DNA Nanotechnology for Drug Delivery

Chapter 4 Regulatory Landscape

Regulatory Paths for Oligonucleotide Therapeutics

U.S.

European Union

Asia-Pacific

Chapter 5 Emerging Technologies

Key Takeaways

Emerging Technologies

Enzymatic Oligonucleotide Synthesis

Advances in RNAi Delivery Systems

Circulating miRNA Diagnostics for Noninvasive Health Monitoring

Innovative Oligonucleotide Conjugation Methods

Pipeline Analysis

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown

Market Analysis by Product Type

Key Takeaways

Oligonucleotide Drugs

Synthesized Oligos

Equipment and Reagents

Services

Market Analysis by Application

Key Takeaways

Diagnostics and Therapeutics

Research

Geographic Breakdown

Market Analysis by Region

Key Takeaways

North America

Europe

Asia-Pacific

Rest of the World

Chapter 7 Competitive Intelligence

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Key Takeaways
Industry Structure
Company Share Analysis of the Global Oligonucleotides Market
Strategic Analysis
Funding Outlook
Chapter 8 Sustainability in the Global Oligonucleotides Market: An ESG Perspective
Introduction to ESG
ESG Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Sources
Abbreviations
Company Profiles
AGILENT TECHNOLOGIES INC.
AJINOMOTO BIO-PHARMA
ALNYLAM PHARMACEUTICALS INC.
ASTELLAS PHARMA INC.
BIOGEN
CHARLES RIVER LABORATORIES
EUROFINS GENOMICS
GENSCRIPT
INTEGRATED DNA TECHNOLOGIES INC.
MERCK KGAA
NOVARTIS AG
NOVO NORDISK A/S
REVVITY
SAREPTA THERAPEUTICS INC.
THERMO FISHER SCIENTIFIC INC.
Emerging Startups/Market Disruptors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Oligonucleotides: Global Markets

Market Research Report | 2026-01-21 | 125 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com